Clinical Trial

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Study acronym: STOP-GAP
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.
Protocol Amendment History 59 amendments
This ClinicalTrials.gov record has been amended 59 times since 2016-06-29; most recent amendment 2026-06-08.
Status change: Not Yet Recruiting → Recruiting 2016-11-01
Trial Details
NCT Number NCT02821013
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Melanoma and Skin Cancer Trials Limited
Conditions Unresectable/Metastatic Melanoma
Enrollment 614 participants
Start Date 2016-10-31
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-09